Core Points - VolitionRx Limited will host a conference call on November 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its Q3 2024 financial and operating results, along with a business update [1][2]. Company Overview - Volition is a multi-national company focused on advancing the science of epigenetics, aiming to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [4]. - The company is developing and commercializing cost-effective blood tests for diagnosing and monitoring various diseases, including certain cancers and conditions associated with NETosis, such as sepsis [5]. Research and Development - Volition's R&D activities are primarily based in Belgium, with additional innovation laboratories and offices located in the U.S., London, and Singapore [6].

Core Insights - VolitionRx Limited has appointed Timothy Still as Chairman of its board of directors, effective November 6, 2024, bringing over 35 years of experience in medical diagnostics and digital health [1][2][3] Company Overview - Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to improving outcomes for people and animals through earlier detection and monitoring of life-altering diseases [5][6] - The company is developing simple, cost-effective blood tests aimed at diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [6][4] Leadership and Experience - Timothy Still has held significant leadership roles in various medical technology companies, including President and CEO of Sense Biodetection, and has a strong track record in guiding companies from R&D to market readiness [2][3] - Cameron Reynolds, President and Group CEO of Volition, expressed enthusiasm about Still's appointment, highlighting his extensive experience in the diagnostic sector [3] Strategic Vision - Timothy Still emphasized the potential of Volition's epigenetic technology to significantly impact global healthcare by improving disease detection and treatment monitoring [3] - The company aims to leverage Still's strategic advice and leadership to drive its next phase of growth [3]

Core Insights - VolitionRx Limited has published findings from its 'NETs in sepsis management' symposium, indicating that Nu.Q® NETs can predict patients at higher risk of deteriorating from sepsis [1][5] Group 1: Research Findings - The symposium presented results from three independent studies conducted in France, Germany, and the Netherlands, involving over 3,000 sepsis patients [2] - All studies utilized Volition's Nu.Q® NETs test to measure circulating H3.1 nucleosomes in the bloodstream, which serve as a surrogate marker for Neutrophil Extracellular Traps (NETs) [2] Group 2: Clinical Implications - Elevated levels of circulating H3.1 nucleosomes in sepsis patients are associated with a dysregulated immune response and increased risks of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock [3] - The use of Nu.Q® NETs to measure elevated H3.1 levels could significantly enhance sepsis management, allowing for timely interventions to improve patient outcomes [5] Group 3: Commercialization Efforts - Volition is actively seeking to commercialize Nu.Q® NETs, with the findings from the studies supporting ongoing licensing discussions with key industry stakeholders [5] - The company aims to introduce Nu.Q® NETs into hospitals, potentially transforming sepsis treatment and improving survival rates and quality of life for survivors [4]

Core Insights - The upcoming webinar on October 21, 2024, will focus on the extensive studies regarding the use of Nu.Q® NETs in sepsis management, involving over 3000 patients and more than 14,000 samples [1][2] - Volition's technology aims to enhance clinical practice in sepsis management by quantifying H3.1 nucleosomes, which are critical in predicting organ failure [3] Company Overview - Volition is a multinational company dedicated to advancing epigenetics and developing cost-effective blood tests for diagnosing and monitoring diseases, including cancer and sepsis [5][6][7] - The company emphasizes the importance of early diagnosis and monitoring to improve patient outcomes and quality of life [7] Technology and Research - The Nu.Q® NETs technology quantifies circulating H3.1 nucleosomes in the bloodstream, serving as a surrogate marker for Neutrophil Extracellular Traps (NETs), which can lead to severe health issues when elevated [3] - Research findings from independent studies will be highlighted in the webinar, showcasing the potential of Nu.Q® NETs in clinical settings [2][3] Event Details - The webinar will be hosted by Soo Romanoff from Edison Group and will include insights from Volition's Chief Medical Officer and Chief Commercial Officer [4] - Registration for the event is available, and it will be recorded for on-demand access [4]

Core Insights - VolitionRx Limited is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, focusing on the use of Nu.Q® NETs for sepsis management [1][2] - The session will be chaired by Professor Djillali Annane, highlighting the potential clinical applications of Volition's Nu.Q® NETs H3.1 assay [2] - Research indicates that elevated levels of H3.1 nucleosomes could be critical in predicting organ failure and improving sepsis management [3] Company Overview - Volition is a multi-national epigenetics company dedicated to advancing early detection and monitoring of diseases, including sepsis [6][7] - The company is developing cost-effective blood tests aimed at diagnosing and monitoring various diseases, with a focus on improving patient outcomes [7] - Volition's research and development activities are based in Belgium, with additional offices in the U.S., London, and Singapore [8] Industry Context - Sepsis is identified as the leading cause of death in hospitals globally, accounting for at least 11 million deaths annually [5] - The symposium at ESICM Lives 2024 will gather experts from over 100 countries, emphasizing the global importance of advancements in sepsis management [5]

Core Points - VolitionRx Limited has appointed Dr. Ethel Rubin as an independent director effective September 30, 2024, and she will also serve on the Audit Committee and Compensation Committee [1][2][3] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [4][5] - The company is developing simple, cost-effective blood tests aimed at diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [5][6] Leadership and Expertise - Dr. Ethel Rubin brings over 20 years of experience in the life sciences sector, having held leadership roles in organizations such as BioFortis, CSA Medical, and Medtronic, contributing to the launch of over 25 commercial products [2][3] - Guy Innes, Interim Chair of Volition, expressed confidence in Dr. Rubin's ability to support the company's commercialization efforts for its epigenetic solutions [3] Technology and Market Potential - Volition's Nu.Q® technology, which is already generating revenue in the animal health sector, has potential applications in human health for early detection and monitoring of diseases like cancer and sepsis [3][5]

Core Insights - VolitionRx Limited reported significant growth in revenue and product sales in the first half of 2024, indicating strong market demand for its Nu.Q® Vet Cancer Test and ongoing advancements in its product pipeline [2][4]. Financial Performance - Revenue for the second quarter of 2024 reached $396,000, an increase of 83% compared to the same period last year [4] - Total revenue for the first half of 2024 was $567,000, reflecting a 55% increase year-over-year [4] - Operating expenses in the second quarter decreased by 24% compared to the prior year, as part of cost reduction measures targeting $10 million in annualized savings [4] - As of June 30, 2024, cash and cash equivalents amounted to approximately $6.0 million [4] - A registered direct offering completed post-quarter raised $7 million in gross proceeds, with potential additional proceeds of up to $14.5 million from milestone-linked warrants [4] Product Development and Market Expansion - The Nu.Q® Vet Cancer Test is now available in 17 countries, with over 60,000 tests sold in the first half of 2024, surpassing the total sales for the entire year of 2023 [2] - The company is actively engaging in commercial discussions with key players in the liquid biopsy, IVD, sepsis, and oncology sectors [2][3] - Progress has been made in preparing the Nu.Q® NETs product for sepsis and the Nu.Q® Lung Cancer and Capture-PCR™ technologies for licensing [3] Strategic Initiatives - The focus for the second half of 2024 includes negotiating the first licensing deal in the human diagnostics space, with PharmaVentures engaged as an advisor to assist in securing these deals [4]

Core Viewpoint - VolitionRx Limited has announced a stock offering that aims to raise approximately $7 million, with potential additional proceeds of up to $14.5 million through milestone-linked warrants, to support its research and development efforts in epigenetics and disease detection [1][4]. Group 1: Offering Details - The company is offering 12,727,273 shares of common stock at an offering price of $0.55 per share, along with milestone-linked warrants [1]. - The milestone-linked series A and B warrants have an exercise price of $0.57 per share and will expire under specific conditions related to significant agreements and FDA approvals [3]. - The offering is expected to close around August 12, 2024, pending customary closing conditions [1]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be approximately $7 million before deducting fees and expenses [4]. - If fully exercised, the milestone-linked warrants could provide an additional $14.5 million in gross proceeds [4]. Group 3: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve disease detection and monitoring [7]. - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including certain cancers and conditions associated with NETosis [8]. - Research and development activities are primarily based in Belgium, with additional offices in the U.S., Nevada, London, and Singapore [9].

PharmaVentures has been engaged to act as an advisor to Volition to help secure licensing deals with industry leaders for both Nu.Q® Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. Adrian Dawkes, Managing Director, PharmaVentures, said: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving li ...

VolitionRx Limited (NYSE:VNRX) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Cameron Reynolds - President, CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Louise Batchelor - Chief Marketing & Communications Officer Conference Call Participants Bruce Jackson - Benchmark Company Tim Moore - EF Hutton Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Richard Deutsch - Sutter Securities Operator Good morning, ladies and gentlemen, and thank you for standing by. We ...